KRAS and lung carcinoma: For instance, the combined use of mTOR inhibitors, IGF1R inhibitors, and ARS-1620 significantly enhanced tumour regression with low toxicity compared to combined MEK inhibitors or ARS-1620 alone in a series of KRAS-driven mouse lung cancer models183.